ϳԹ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • ϳԹ News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Aug 6 2026 UPDATED 9:08 AM

Full Issue

Moderna Prepping Newly Approved MRNA Flu Vaccine For 2026-27 Respiratory Virus Season

The shot, initially approved for people 50-64, "will allow us to rapidly adjust to rapidly emerging new flu strains, a capacity we have not had before,” said Dr. Georges C. Benjamin of the American Public Health Association.

The Food and Drug Administration on Wednesday approved the first mRNA flu vaccine, enabling use of a technology that will make it easier to rapidly target a widely prevalent or particularly virulent strain of the virus. The approval of the vaccine, called mFLUSIVA, which is manufactured by Moderna, follows a series of blows to mRNA research directed by Health Secretary Robert F. Kennedy Jr., including the cancellation of 22 projects meant to develop vaccines with mRNA technology through the government’s Biomedical Advanced Research and Development Authority. (Jewett, 8/5)

Also —

Vaccine maker Moderna said late last week that a phase 3 trial for its investigational mRNA norovirus vaccine candidate did not meet statistical criteria for early success. But the trial will continue. (Dall, 8/3)

As vaccine hesitancy continues to rise, fueling a record-breaking resurgence of measles, among other public health threats, an online tool launched this week aims to help people better understand vaccine safety. The free and interactive tool -- called "What's the Risk?" -- was created by the University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP) and Unbiased Science. (Henderson, 8/5)

Texas Attorney General Ken Paxton has launched an investigation into the American Academy of Pediatrics, alleging the organization may have promoted childhood vaccines for financial gain. According to a Wednesday announcement from Paxton’s office, the investigation centers on whether the nation’s largest professional association of pediatricians issued vaccine recommendations influenced by financial relationships with pharmaceutical companies rather than scientific evidence. (Taylor, 8/5)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, August 6
  • Wednesday, August 5
  • Tuesday, August 4
  • Monday, August 3
  • Friday, July 31
  • Thursday, July 30
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • ϳԹ
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF